Abstract

Introduction: Identifying prognostic factors is essential for proper postoperative patient monitoring with upper urinary tract carcinoma, that would contribute to the decision-making process regarding the application of adjuvant chemotherapy after radical nephroureterectomy. Aim: To investigate demographic, clinical, and pathological prognostic factors of cancer-specific survival (CSS) for upper urothelial tumors. Methods: A retrospective cohort study was conducted including 342 patients who underwent radical nephroureterectomy. Kaplan-Meier method and LogRank test were used to assess survival. Cox regression analysis was used to determine the impact of different factors on cancer-specific survival after radical nephroureterectomy. Results: The study cohort consisted of 342 patients, with a mean follow-up time after radical nephroureterectomy of 32.5 (6-154) months. The 5-year CSS was 64% for this patient cohort. During the follow-up period, a total of 128 (37.4%) patients died, including 92 (28.2%) patients who died due to urothelial carcinoma. Multivariate analysis showed that the pathological stage of the primary tumor (HR, 11.1; 95% CI 3.64-33.8; P=0.001), presence of positive lymph nodes (HR, 2.04; 95% CI 1.05-3.94; P=0.03) and preoperative anemia (HR, 3.50; 95% CI 2.02-6.08; P=0.001) were independent predictors significantly associated with worse CSS. Patients with disease stage ≤ pT2 had significantly better CSS compared to patients with disease stage ≥ pT3 (P=0.001, Log-Rank test). The average CSS for patients with positive lymph nodes (pN+) was 22.1 ± 5.1 months (95% confidence interval from 12.1-32.2). Conclusion: Preoperative anemia, pathological disease stage, and presence of positive lymph nodes are significant independent prognostic predictors of CSS in patients who underwent radical nephroureterectomy (RNU).

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.